Navigation Links
Caliper Awarded New Task Order for EPA ToxCast Program
Date:11/9/2009

s ToxCast program, which is expected to cover the screening of approximately 700 environmental compounds, in contrast to Phase I which covered approximately 320 compounds. The task order we just received involves screening this new compound set against a panel of 81 G-Protein Coupled Receptor (GPCR) assays, which is a subset of Caliper's current ToxCast assay panel of 275 assays in total. The EPA expanded Caliper's original Phase I ToxCast panel of 235 assays in the third quarter with the addition of 40 new kinase and other enzyme assays. All of these new assays are performed on Caliper's LabChip EZ Reader® instrument, which reflects the high quality of data obtained with our LabChip systems," commented David Manyak, Executive Vice President, Drug Discovery Services.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.

The statements in this press release regarding future events, including statements regarding Caliper's expectations regarding its future role in the EPA's ToxCast program, Caliper's belief that its funded activities under the ToxCast program will continue to expand, Caliper's belief that the recently received task order from the EPA will produce strong double-digit growth in its CDAS business unit in 2010, and Caliper's belief
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration
2. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
3. Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
4. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
5. B. Braun Awarded Contract With HealthTrust Purchasing Group to Provide Pain Management Solutions
6. Noninvasive Medical Technologies Awarded ISO 13485 Quality Certification
7. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
8. SRI International Awarded National Institute of Mental Health Contract for Evaluation of Brain Imaging Agents and Medications for Treatment of Mental Disorders
9. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
10. AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis
11. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2010)... Vermillion, Inc. (Nasdaq: VRML ), a molecular diagnostics company, will host ... issuance of Q2 financial results on Monday, August 16, 2010 . ... Conference Call Information ... To access the ... United States and Canada or +1 212 231 2901 ...
(Date:7/29/2010)... response to the agreement announced that CVS Caremark would provide pharmacy ... the National Community Pharmacists Association (NCPA) issued the following statement from ... H. Harmison , PD: , ... (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20100106/DC33253LOGO ) , ...
(Date:7/29/2010)... , July 29 ... from a Phase Ib/II clinical trial in ... unique, investigational new drug for the treatment ... endpoint demonstrating that ITI-007 was safe and ... addition, several exploratory endpoints were evaluated. Treatment ...
Breaking Medicine Technology:Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010 2Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010 3NCPA Statement on CVS Caremark-Aetna Agreement 2NCPA Statement on CVS Caremark-Aetna Agreement 3Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia 2Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia 3Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia 4Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia 5Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia 6Nautilus IDScan net Presents New Drivers 26apos 3B License Parsing Component a Magic Tool for Software Developers 71238 1Nautilus IDScan net Presents New Drivers 26apos 3B License Parsing Component a Magic Tool for Software Developers 71238 2Nautilus IDScan net Presents New Drivers 26apos 3B License Parsing Component a Magic Tool for Software Developers 71238 3Nautilus IDScan net Presents New Drivers 26apos 3B License Parsing Component a Magic Tool for Software Developers 71238 4Nautilus IDScan net Presents New Drivers 26apos 3B License Parsing Component a Magic Tool for Software Developers 71238 5MarijuanaDoctors com Announces Weed Team Contest Winner Adds Additional Trip to the Cannabis Cup in Amsterdam 71236 1MarijuanaDoctors com Announces Weed Team Contest Winner Adds Additional Trip to the Cannabis Cup in Amsterdam 71236 2MarijuanaDoctors com Announces Weed Team Contest Winner Adds Additional Trip to the Cannabis Cup in Amsterdam 71236 3New Book Reveals the Powerful and Undermining Impact of Stress on Good Decision Making and What Leaders Can Do About It 71233 1New Book Reveals the Powerful and Undermining Impact of Stress on Good Decision Making and What Leaders Can Do About It 71233 2New Book Reveals the Powerful and Undermining Impact of Stress on Good Decision Making and What Leaders Can Do About It 71233 3
... Oncolytics,Biotech Inc. ("Oncolytics") announces that a poster by ... York, entitled "In Vivo Synergy between,Oncolytic Reovirus and ... be presented today at the American,Association for Cancer ... meeting runs from April 14-18, 2007. , The ...
... WIRE)--Apr 17, 2007 - ZIOPHARM Oncology,Inc. (NASDAQ: ... strongly supportive of the development of an ... high,bioavailability when administered orally; in addition it ... to oral,administration. These data were presented in ...
Other Medicine Technology:Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 2Oncolytics Biotech Inc. Research Collaborators Demonstrate,Reovirus/Gemcitabine Combination Has Synergistic Effect Against,Human Colon Cancer Cell Lines 3ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 2ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR 3
(Date:7/29/2010)... NY, July 30, 2010Thirty million women will benefit from ... either through new or strengthened insurance coverage, according to ... first analysis of its kind, the authors report that ... to health costs that women now experience by subsidizing ... women, and strengthening existing coverage for 14.5 million women ...
(Date:7/29/2010)... Researchers seeking to learn more about stroke by studying how ... week releasing new findings that they hope will aid in ... , The Japanese team is reporting in a ... they are optimistic that inhibiting a protein found on the ... irregular blood clotting and the spread of certain cancers throughout ...
(Date:7/29/2010)... the first time a cell-of-origin for human prostate ... predictive and diagnostics tools and the development of ... disease. , The researchers, from UCLA,s Jonsson Comprehensive ... benign prostate tissue could become human prostate cancer ... that bucks conventional wisdom. It had been widely ...
(Date:7/29/2010)... and Drug Administration (FDA) received reports of malignancies in ... concerns of an associated risk and prompting an investigation. ... reports of malignancy in children using infliximab, etanercept, and ... issue of Arthritis & Rheumatism , a journal ... FDA has approved 3 TNF blockers for use in ...
(Date:7/29/2010)... brain cells remain diverse and "fit" enough for storing ... Neuron , a new study led by Dr. Inna ... Aviv University describes what makes some memories stick. , ... that occurs in the brain, which could be the ... can generate, the new study has found. The understanding ...
Breaking Medicine News(10 mins):Health News:30 million women to benefit from health reform law 2Health News:30 million women to benefit from health reform law 3Health News:30 million women to benefit from health reform law 4Health News:Snake venom studies yield insights for development of therapies for heart disease and cancer 2Health News:Snake venom studies yield insights for development of therapies for heart disease and cancer 3Health News:Snake venom studies yield insights for development of therapies for heart disease and cancer 4Health News:UCLA scientists for the first time identify a cell-of-origin for human prostate cancer 2Health News:UCLA scientists for the first time identify a cell-of-origin for human prostate cancer 3Health News:TNF blockers may increase the risk of malignancy in children 2Health News:TNF blockers may increase the risk of malignancy in children 3Health News:Memory's master switch 2Health News:Memory's master switch 3
... Call Today at 8 a.m. EDT, CARLSBAD, ... Inc. (Nasdaq: ISIS ) and Genzyme Corp. ... has provided guidance regarding approval,requirements for mipomersen. The ... acceptable surrogate endpoint for accelerated,approval of mipomersen for ...
... April 25 Universal,Health Realty Income Trust (NYSE: ... 31, 2008, net income was $4.2 million, or $.35 ... per diluted share, during the,same quarter in the prior ... of 2008 was increased depreciation expense of $329,000,or $.03 ...
... Today, on World Malaria,Day, the American Red Cross ... a robust global response to this deadly disease., ... approximately 300 million people, mostly children in Africa. More,than ... disease., Since 2001, the American Red Cross and ...
... aging ... friendship and fun, FULLERTON, Calif., April 25 Women from coast-to-coast,and ... Hat Society (RHS), founded 10 years ago today, perceptions began,to change. In ... hats and purple outfits in the spirit of having fun at 50 ...
... United Healthcare,Workers - West and Motion Picture & Television ... on a new five-year contract, which,provides stable and predictable ... MPTF Hospital and Health Centers through October,2012. The agreement ... to its membership, and ratification is expected by the,end ...
... breast cancers that depend on hormones and those ... April 25th in the open-access journal PLoS Genetics. ... cancers, which usually require treatment with surgery and ... as hormone independent breast cancers, which are treated ...
Other Medicine News:Health News:FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen 2Health News:FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen 3Health News:FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen 4Health News:FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen 5Health News:FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen 6Health News:Universal Health Realty Income Trust Reports 2008 First Quarter Financial Results 2Health News:Universal Health Realty Income Trust Reports 2008 First Quarter Financial Results 3Health News:Universal Health Realty Income Trust Reports 2008 First Quarter Financial Results 4Health News:Universal Health Realty Income Trust Reports 2008 First Quarter Financial Results 5Health News:Universal Health Realty Income Trust Reports 2008 First Quarter Financial Results 6Health News:Universal Health Realty Income Trust Reports 2008 First Quarter Financial Results 7Health News:Universal Health Realty Income Trust Reports 2008 First Quarter Financial Results 8Health News:Uniting to Fight Malaria Around the World 2Health News:Uniting to Fight Malaria Around the World 3Health News:Hats Off to the Red Hat Society, Which Turns 10 Today 2Health News:Hats Off to the Red Hat Society, Which Turns 10 Today 3Health News:Settlement Reached Between Motion Picture & Television Fund and SEIU UHW 2
... is a formulation of iopamidol ... by oral administration or, where necessary, ... considerable improvement in the radiological exploration ... traditional contrast media. Thanks to its ...
... dimeglumine) is a paramagnetic MRI contrast agent. ... gadobenate, a chelating agent that forms a ... ion. It is salified with meglumine forming ... all the physico-chemical features typical of gadolinium ...
... GastroMARK (generic name: ferumoxsil) is Advanced ... distinguish the loops of the bowel from ... of organs and tissues in the abdomen ... organs and tissues cannot be easily distinguished ...
... Up to 20% of the ... the U.S. are suboptimal. Activated DEFINITY ... clearer images of the heart than ... activated DEFINITY improves diagnostic quality for ...
Medicine Products: